- News Library
- Servier Medical Art
- Partnering & Licensing
Jacques Servier ends the collaboration between Jean-Philippe Seta and Servier04/10/2013
Suresnes, October 4, 2013
Due to differences of opinion with Dr Jacques Servier on corporate strategy and vision for the future, Dr Jean-Philippe Seta, CEO of Servier, will as of today no longer continue his functions.
After joining Servier as Clinical Research Project Leader in the Lung Diseases Department in 1984, Dr Seta was promoted to International Medical Director in 1988, International Managing Director in 1991, Chief Operating Officer in 1997, and, in 2003, Chief Executive Officer. Dr Seta greatly contributed to the international expansion of Servier, which is now present in 140 countries.
The company’s Executive Committee, of which Dr Seta was a member will continue to function, presided over as before by Dr Servier.
Servier is the leading independent French pharmaceutical company with a turnover of €3.9 billion in 2012. 92% of Servier’s medicines are prescribed outside of France, and in 2012 Servier contributed 57% of France’s trade balance in the pharmaceutical sector. Since early 2012, Servier has entered into 14 partnerships with biotechnology companies and public and private research institutions around the world, for innovative drug research and development in the fields of cardiovascular medicine, neurology, rheumatology, autoimmune diseases, and, particularly, oncology, with several candidate drugs in clinical development.